Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the years, but the range of approved drugs has expanded. Semaglutide and tirzepatide are the most commonly used today. Primary care providers play an important role in the individualized medical management of overweight patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Diagnostics of respiratory viral infections
What is tested when and on whom?
- Incontinence
Fecal incontinence from the perspective of gastroenterology
- HER2-positive breast cancer
ENPP1 as a biomarker for poor prognosis and early detection of brain metastases
- Update 2025
Hypercholesterolemia
- GPP: from molecular principles to targeted therapy
Therapeutic rationale for targeted IL-36 receptor inhibition
- HFpEF 2025
Precision medicine and phenotypes
- Myelofibrosis
New treatment options for myelofibrosis patients with a high risk of anemia?
- Chronic insomnia in adults: Guideline recommendations